SAREUM HOLDINGS PLC : First Patent Grant for Sa...

(AIM: SAR)

10 November 2014

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

First Patent Grant for Sareum's TYK2 Kinase Inhibitor Programme

Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the European Patent Office has issued notification of a grant of a patent for inventions associated with Sareum's TYK2 Kinase Inhibitor Programme.

This patent* describes compounds that inhibit JAK kinase enzyme function, in particular TYK2 kinase. It also describes the use of these compounds in the treatment of disease mediated by these kinase enzymes, including autoimmune diseases such multiple sclerosis, psoriasis and inflammatory bowel disease.

The granting of this patent means that Sareum will have approved patent protection in Europe for its TYK2 inhibitor programme.  The Company expects that similar patents will be granted in other major markets, including the USA, in due course.

These compounds were generated from Sareum's SKIL® (Sareum Kinase Inhibitor Library) drug discovery technology platform. SKIL so far produced the Company's Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

* Patent No. EP2634185

Sareum's Chief Scientific Officer, Dr John Reader, commented: "The granting of this patent in Europe demonstrates the strength of the intellectual property for our TYK2 programme and enhances our negotiating position with potential licensing partners."

Enquiries: Sareum Holdings plc
Tim Mitchell	01223 497 700
Sanlam Securities UK Limited (Nomad)
Simon Clements / James Thomas	020 7628 2200
Hybridan LLP (Broker)
Claire Noyce / William Lynne	0203 713 4581/ 4582
The Communications Portfolio (Media enquiries)
Ariane Comstive [e-mail]	020 7536 2028

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

- Ends -

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SAREUM HOLDINGS PLC via Globenewswire

HUG#1869934